#COVID19 $BNTX $PFE BioNTech and Pfizer completed dosing for the first cohort (12 participants) of their Phase 1/2 trial of BNT162 (COVID-19 vaccine) in Germany.

The dose escalation portion of the Phase 1/2 trial will include ~200 healthy subjects.

https://t.co/3P9xeaJdWj